ca188ec2-4185-4871-b71b-d024a37e5654
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.300
- KRAS_SIGNALING_DN+0.300
- MYOGENESIS+0.300
- ALLOGRAFT_REJECTION+0.200
- APICAL_JUNCTION+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
- INTERFERON_ALPHA_RESPONSE+0.200
- MYC_TARGETS_V2+0.200
- PANCREAS_BETA_CELLS+0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200
Top 10 suppressed
- PROTEIN_SECRETION-0.500
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.400
- MITOTIC_SPINDLE-0.400
- TGF_BETA_SIGNALING-0.400
- UV_RESPONSE_DN-0.400
- ANDROGEN_RESPONSE-0.300
- MYC_TARGETS_V1-0.300
- NOTCH_SIGNALING-0.300
- ANGIOGENESIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0720 | Med | Medulloblastoma | 0.862 |
| 2 | TCGA-E9-A3X8-01A-31R-A22U-07 | — | B | 0.840 |
| 3 | MNG718 | — | — | 0.840 |
| 4 | edef6762-dd96-4284-81e6-2e128af287fa | — | — | 0.839 |
| 5 | MNG1103 | — | — | 0.832 |
| 6 | 84f39507-9883-4bab-98f9-8bd72d2aee7b | — | — | 0.819 |
| 7 | TCGA-A7-A56D-01A-11R-A27Q-07 | — | B | 0.815 |
| 8 | SJEPD001516_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.814 |
| 9 | SJEPD006_D.RNA-Seq | EPN | Supratentorial EPN | 0.797 |
| 10 | SJEPD001512_D1.RNA-Seq | EPN | Supratentorial EPN | 0.787 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |